In June, Cereno Scientific CMO and Head of R&D Rahul Agrawal spoke with Clinical Leader Executive Editor Abby Proch about the scientific and strategic rationale behind extending the company’s Phase IIb study duration. He also shares how patient input, regulatory guidance, and earlier-phase data shaped a design intended to generate more meaningful and durable insights in a complex, heterogeneous disease.

Read the full article here.